UroGen Pharma (URGN) Payables (2016 - 2025)
Historic Payables for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $26.2 million.
- UroGen Pharma's Payables rose 3295.91% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 3295.91%. This contributed to the annual value of $27.4 million for FY2024, which is 6586.65% up from last year.
- Per UroGen Pharma's latest filing, its Payables stood at $26.2 million for Q3 2025, which was up 3295.91% from $31.0 million recorded in Q2 2025.
- UroGen Pharma's Payables' 5-year high stood at $31.0 million during Q2 2025, with a 5-year trough of $8.6 million in Q2 2022.
- Over the past 5 years, UroGen Pharma's median Payables value was $16.4 million (recorded in 2023), while the average stood at $17.1 million.
- As far as peak fluctuations go, UroGen Pharma's Payables plummeted by 1638.95% in 2022, and later skyrocketed by 8969.58% in 2023.
- Over the past 5 years, UroGen Pharma's Payables (Quarter) stood at $12.1 million in 2021, then grew by 2.32% to $12.4 million in 2022, then surged by 33.55% to $16.5 million in 2023, then skyrocketed by 65.87% to $27.4 million in 2024, then dropped by 4.59% to $26.2 million in 2025.
- Its last three reported values are $26.2 million in Q3 2025, $31.0 million for Q2 2025, and $30.3 million during Q1 2025.